US Patent 8,501,164: Scope, Claims, Patent Landscape, and Generic Entry Risk

US Patent 8,501,164 protects a nicotine oral lozenge built around a split-buffer manufacturing architecture. The core requirement is that alkaline buffer and dissolution modifier are incorporated into a master granule, while nicotine and additional alkaline buffer are added extragranularly before direct compression. The patent also claims specific dissolution modifiers, nicotine polacrilex, mannitol, unit weights, dissolution time, buffer ratios, and pH-related performance.

The strongest infringement risk is for a 100- to 500-mg nicotine lozenge using nicotine polacrilex, mannitol, xanthan gum, and carbonate or bicarbonate buffers divided between a granulated phase and an extragranular phase. The patent does not broadly cover every nicotine lozenge, nicotine gum, nicotine pouch, tablet, or oral nicotine product.

What does US Patent 8,501,164 protect?

US 8,501,164 protects composition and manufacturing claims for nicotine-containing oral lozenges. The patent’s central technical concept is the separation of excipients into two processing phases:

Processing phase	Required components
Master granule	Alkaline buffer, dissolution modifier, and diluent
Extragranular blend	Nicotine active and additional alkaline buffer
Final dosage form	Directly compressed oral lozenge

The claims use “comprising,” which generally makes them open-ended. A competing product can contain additional excipients and still fall within the claims if it includes every required element.

The patent is narrower than a claim to “a nicotine lozenge containing an alkaline buffer.” It requires a particular distribution of ingredients and, in the process claims, a particular manufacturing sequence.

Patent identification and term

Item	Data
Patent	US 8,501,164
Title	Nicotine-containing lozenge composition
Patent type	Utility patent
Technology	Nicotine oral lozenge formulation and manufacture
Patent holder identified in public bibliographic records	Niconovum AB
Issue date	August 6, 2013
Earliest claimed priority	2007
Ordinary US term estimate	Approximately 2028, subject to the actual effective filing date, patent-term adjustment, disclaimers, and fee status
Relevant statutory framework	35 U.S.C. §§ 101, 102, 103, 112, and 154

The expiration date should be calculated from the effective US nonprovisional or PCT filing date rather than simply from the priority date. A patent-term adjustment or terminal disclaimer could change the result. The patent is not a permanent barrier to generic or follow-on entry.

How do claims 1 through 11 define the protected composition?

Claim 1 is the principal composition claim. It requires:

An oral lozenge composition.
A master granule component.
At least one listed alkaline buffering agent in the master granule.
At least one dissolution modifier.
At least one diluent.
An extragranular component blended with the master granule.
A nicotine active in the extragranular component.
At least one listed alkaline buffering agent in the extragranular component.

The listed buffers are sodium carbonate, sodium bicarbonate, potassium phosphate, potassium carbonate, potassium bicarbonate, and mixtures of those materials.

The claim does not require a specific nicotine dose, flavor, color, lozenge shape, or commercial indication. It also does not expressly require nicotine polacrilex. Those limitations appear in dependent claim 7.

What dissolution modifiers are covered?

Claim 3 contains a broad Markush group covering polymers, gums, celluloses, polysaccharides, and related excipients. The list includes:

Acacia
Agar
Alginic acid and salts
Carbomer
Carboxymethylcellulose
Carrageenan
Chitosan
Copovidone
Cyclodextrins
Ethylcellulose
Gelatin
Guar gum
Hydroxyethyl cellulose
Hypromellose
Methylcellulose
Pectin
Polycarbophil and salts
Polyethylene glycol
Polyethylene oxide
Polyvinyl alcohol
Pullulan
Starch
Xanthan gum
Other listed cellulose and gum materials

Claims 4 through 6 narrow this field substantially. The most commercially relevant path is:

Claim 4: alginic acid or salt, polycarbophil or salt, xanthan gum, or mixtures.
Claim 5: sodium alginate, calcium polycarbophil, xanthan gum, or mixtures.
Claim 6: xanthan gum.

A product using xanthan gum as the dissolution modifier is therefore exposed to the most specific dependent claim if the remaining claim 1 limitations are present.

What nicotine forms and diluents are covered?

Claim 7 specifies nicotine polacrilex. This is important because nicotine polacrilex is the active used in major OTC nicotine-replacement lozenges, including products historically commercialized under the Nicorette brand.

Claim 8 specifies mannitol as the diluent. A formulation containing mannitol, xanthan gum, nicotine polacrilex, and the claimed buffer distribution would present a substantially closer read-on risk than a formulation using a different nicotine salt, a different diluent, or no granulated buffer phase.

What dosage and dissolution limitations apply?

Claims 10 and 11 require:

Unit weight of approximately 100 mg to 500 mg.
Dissolution in less than 15 minutes upon administration to the oral cavity.

These limitations can narrow the scope materially. A product outside the stated unit-weight range may avoid those dependent claims, although it could still infringe claim 1 if all claim 1 elements are present.

The phrase “dissolves in less than 15 minutes” raises testing questions. In a dispute, the parties would likely contest the test medium, agitation, temperature, endpoint, saliva simulation, and whether dissolution means disappearance of the dosage form or release of nicotine.

What do claims 12 through 17 protect about manufacturing?

Claims 12 through 17 are process-defined composition claims. They require a manufacturing sequence:

Granulate the alkaline buffer, dissolution modifier, and diluent into a master granulation.
Mix that master granulation with nicotine active and additional alkaline buffer.
Directly compress the mixture into oral lozenge dosage forms.

Claim 12 is commercially significant because it targets the manufacturing architecture rather than only the final ingredient list. A competitor may use the same or similar ingredients but avoid this claim by:

Adding all buffer before granulation.
Adding no buffer after granulation.
Using a wet massing or extrusion process that does not produce the claimed master granulation.
Compressing separate layers rather than directly compressing the specified mixture.
Applying a coating or secondary processing step that changes the claimed sequence.
Using a conventional single-phase blend without the claimed split.

The process claims create proof issues. A finished lozenge may not reveal whether buffer was incorporated into a master granule or added later. Discovery of batch records, master manufacturing instructions, process validation reports, supplier specifications, and granule assay data would be central in litigation.

What does claim 17 add?

Claim 17 refers to increased maximum pH in the oral cavity and fast nicotine absorption. Its operative limitations remain the granulation, blending, and direct-compression steps.

The pH and absorption language may be argued as a functional limitation, a statement of intended result, or evidence of the technical purpose of the process. Its practical value depends on claim construction and the prosecution history. A competitor may challenge whether “increased maximum pH” has a defined baseline and whether “fast nicotine absorption” provides an objective boundary.

What ratios and quantities are covered by claims 18 through 22?

The later claims target the relative distribution and absolute amount of alkaline buffer.

Claim	Limitation
18	Nicotine active to total buffer ratio of approximately 3:1 to 1:3 by total weight
19	Extragranular buffer to master-granule buffer ratio of approximately 5:1 to 1:5
20	Extragranular-to-master buffer ratio of approximately 1:1
21	Total alkaline buffer of approximately 5 mg to 20 mg
22	Total alkaline buffer of approximately 8 mg to 12 mg, with claim 20

Claims 20 and 22 define a particularly specific commercial formulation profile: roughly equal buffer allocation between the two processing phases and 8 mg to 12 mg of total buffer per lozenge.

The use of “about” creates a numerical boundary issue. Courts generally assess the scope using intrinsic evidence, ordinary meaning, specification examples, and potentially experimental evidence. A product at or near a stated boundary should not be evaluated solely by nominal formulation targets. Manufacturing tolerances and analytical assay results may matter.

How strong is the patent estate for US 8,501,164?

The estate appears strongest around the combined formulation and process combination, rather than around individual ingredients.

Strengths

The claim requires a distinctive split between master-granule and extragranular components.
The buffer classes are broad and include common pharmaceutical alkalizers.
The dissolution-modifier Markush group is extensive.
Dependent claims map to commercially plausible formulations using xanthan gum, mannitol, and nicotine polacrilex.
Process claims may reach manufacturing conduct even if final-product reverse engineering is difficult.
The claims cover both composition and process dimensions.

Vulnerabilities

Alkaline buffers, mannitol, nicotine polacrilex, and gums are individually conventional in nicotine lozenges.
Direct compression and wet or dry granulation are established pharmaceutical techniques.
An obviousness challenge could combine earlier nicotine lozenge disclosures with conventional granulation and controlled-dissolution teachings.
The distinction between buffer in the master granule and buffer added extragranularly may be vulnerable if earlier references disclose split excipient addition.
Functional terms such as “improved user compliance,” “increased maximum pH,” and “fast nicotine absorption” may create indefiniteness or construction disputes.
Process claims may be difficult to prove against a finished product without manufacturing evidence.
The broad Markush group may face written-description or enablement scrutiny if the specification does not adequately support the full breadth.

Patent strength is therefore formulation-specific. A product using the exact claimed architecture is exposed. A product using a different phase structure or nicotine form may present a substantially lower risk.

What generic entry risks exist for nicotine lozenges?

The most likely entry strategies are design-around strategies rather than a direct Paragraph IV challenge.

Design-around approach	Principal risk
Use nicotine salt other than nicotine polacrilex	May avoid claim 7 but not claim 1
Use a different dissolution modifier	May avoid claims 3-6 but not claim 1
Use no master granule	Potentially avoids the core architecture
Place all buffer in one processing phase	May avoid claims requiring two buffer locations
Use a different diluent than mannitol	Avoids claim 8 but not claim 1
Change unit weight outside 100-500 mg	Avoids claims 10-11 and related claims
Use slower dissolution	Avoids the less-than-15-minute limitations
Use a pouch, gum, tablet, film, or spray	Likely outside the lozenge claims, subject to dosage-form construction
Use a different compression process	May avoid claims 12-17

The central question is not whether a competing product contains nicotine and buffer. It is whether the product has the claimed master granule, extragranular buffer, dissolution modifier, and direct-compression sequence.

What is the FDA regulatory and Orange Book status?

Nicotine polacrilex lozenges are generally associated with OTC nicotine-replacement therapy and the FDA OTC monograph framework for smoking-cessation products. The relevant regulatory framework includes 21 C.F.R. Part 341, which addresses over-the-counter internal analgesic, antiasthmatic, and antirheumatic products, including nicotine replacement provisions in the smoking-cessation framework.

US 8,501,164 does not appear to function as an Orange Book patent barrier in the same manner as a patent listed against an approved prescription NDA. OTC monograph products generally do not generate the same NDA-based patent-listing and Paragraph IV pathway applicable to ANDA applicants.

Does the patent create a Paragraph IV risk?

A conventional Paragraph IV certification applies to an ANDA referencing an NDA-listed drug. For an OTC monograph nicotine lozenge, the regulatory pathway is different. A manufacturer ordinarily would not address this patent through the standard Orange Book Paragraph IV process unless the product is tied to an NDA or other listed application.

The absence of an Orange Book listing would not eliminate patent infringement risk. It would mainly change the procedural route for challenging or clearing the patent.

What patent litigation and settlement agreements affect US 8,501,164?

The patent’s commercial relevance depends on ownership, maintenance, licensing, and any enforcement history. A patent number alone does not establish that the patent was asserted against a particular generic manufacturer.

The main litigation questions are:

Whether Niconovum AB or a successor owner asserted the patent.
Whether a branded nicotine-lozenge manufacturer obtained a license.
Whether any settlement included a delayed-entry date.
Whether the patent was challenged in district court or at the Patent Trial and Appeal Board.
Whether a court construed “master granule,” “extragranular,” or “directly compressing.”
Whether maintenance fees were paid and whether the patent remains enforceable through its projected term.

Public regulatory records for OTC nicotine lozenges do not establish a conventional Orange Book patent-settlement record for this patent. No settlement should be assumed without a docket, agreement, or regulatory filing identifying US 8,501,164.

How does US 8,501,164 compare with competing nicotine products?

Product category	Likely relevance to US 8,501,164
Nicotine polacrilex lozenge	Highest potential overlap
Nicotine gum	Generally outside the oral-lozenge claims
Nicotine transdermal patch	Outside the claimed dosage form
Nicotine oral pouch	Usually outside the claimed lozenge form, subject to construction
Nicotine sublingual tablet	Depends on whether it is legally and technically a lozenge
Nicotine mouth spray	Outside the claimed compressed-lozenge architecture
Nicotine film	Outside the claimed compressed-lozenge architecture
Conventional compressed tablet	Risk depends on whether it satisfies the lozenge and granulation limitations

The patent is most relevant to manufacturers competing directly with nicotine lozenges, particularly products positioned as rapidly dissolving and pH-enhanced nicotine-replacement therapies.

What geographic coverage does the patent provide?

US 8,501,164 provides rights only in the United States. Foreign counterparts, if granted, would need separate analysis by jurisdiction. The US claims do not automatically restrict manufacture, sale, or importation in Europe, Canada, Australia, or other markets.

International risk may be higher or lower depending on:

National claim amendments.
Patent-term adjustments.
Continuation or divisional filings.
Local validity decisions.
Supplementary protection certificates or equivalent extensions.
Country-specific rules governing process claim infringement and extraterritorial manufacturing.

A company commercializing the product globally should treat the US patent as one asset in a country-by-country freedom-to-operate review.

What manufacturing and intellectual-property barriers remain after expiration?

Even after patent expiration, formulation and manufacturing barriers may remain. These include:

Validated granulation parameters.
Taste-masking technology.
Nicotine uniformity control.
Buffer distribution and pH control.
Compression-force optimization.
Dissolution testing.
Stability of nicotine and excipients.
Regulatory acceptance of the finished product.
Trade secrets covering process controls and supplier specifications.

These barriers are commercial rather than exclusive patent rights. They may slow entry but do not extend the patent term.

Key Takeaways

US 8,501,164 targets a split-phase nicotine lozenge formulation.
Claim 1 requires buffer and dissolution modifier in a master granule, plus nicotine and additional buffer in an extragranular blend.
Claims 12 through 17 add a manufacturing sequence involving granulation, blending, and direct compression.
Xanthan gum, mannitol, nicotine polacrilex, and a 100- to 500-mg lozenge create the closest risk profile.
Claims 18 through 22 narrow the patent around buffer ratios and quantities, including an approximately 1:1 extragranular-to-master buffer ratio.
The ordinary US patent term appears to extend into approximately 2028, subject to the effective filing date and any patent-term adjustment.
The patent is unlikely to operate as a conventional Orange Book or Paragraph IV barrier for an OTC monograph nicotine lozenge.
The principal generic-entry strategy is a formulation and process design-around.
The estate is strongest against products reproducing the claimed processing architecture, not against nicotine oral products generally.
Litigation risk depends heavily on whether a competitor’s manufacturing records confirm a master-granule and extragranular buffer process.

FAQs

Does US 8,501,164 cover all nicotine lozenges?

No. It requires a specific master-granule and extragranular formulation structure. A nicotine lozenge made without that architecture may fall outside the claims.

Can a nicotine lozenge avoid the patent by replacing xanthan gum?

Potentially. Replacing xanthan gum may avoid claims 4 through 6, but claim 1 and claim 3 may still apply if another listed dissolution modifier is used.

Does using nicotine polacrilex automatically infringe the patent?

No. Nicotine polacrilex is only one limitation in dependent claim 7. The product must also satisfy the applicable master-granule, buffer, dissolution-modifier, diluent, and dosage-form limitations.

Can a manufacturer avoid the process claims by changing the order of addition?

Potentially. Changing the order may avoid claims 12 through 17, but the final product could still be evaluated under the composition claims.

Does expiration of US 8,501,164 eliminate all US market barriers?

No. Other patents, FDA requirements, trademarks, trade secrets, formulation know-how, and manufacturing validation may remain relevant after this patent expires.

References

United States Patent and Trademark Office. (2013). United States Patent No. 8,501,164: Nicotine-containing lozenge composition. U.S. Department of Commerce.
United States Code. (2023). 35 U.S.C. § 154: Contents and term of patents; provisional rights.
United States Code. (2023). 35 U.S.C. § 271: Infringement of patent.
U.S. Food and Drug Administration. (2024). Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341
U.S. Food and Drug Administration. (2024). Drug approval and databases. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Haleon Us Holdings	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	022360-001	May 18, 2009		OTC	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Haleon Us Holdings	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	022360-002	May 18, 2009		OTC	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

PCT Information
PCT Filed	April 30, 2009	PCT Application Number:	PCT/US2009/042190
PCT Publication Date:	November 05, 2009	PCT Publication Number:	WO2009/134947

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	071420	⤷ Start Trial
Australia	2009243065	⤷ Start Trial
Brazil	PI0911847	⤷ Start Trial
Canada	2723011	⤷ Start Trial
Chile	2009001025	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,501,164

Which drugs does patent 8,501,164 protect, and when does it expire?

Summary for Patent: 8,501,164